We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience.
- Authors
Doshi, Peter; Jefferson, Tom; Mar, Chris Del
- Abstract
The article provides information on the failure of influenza antiviral Tamiflu (oseltamnivir) to reduce complications. The U.S. Food and Drug Administration (FDA) mentioned that Tamiflu had been revealed to lessen complications and needed an explicit statement label of the drug to that effect. The FDA cited F. Hoffmann-La Roche Ltd., the manufacturer of Tamiflu, for violating the law of claims made to the contrary.
- Subjects
UNITED States; INFLUENZA treatment; OSELTAMIVIR; F. Hoffmann-La Roche Ltd.; UNITED States. Food &; Drug Administration
- Publication
PLoS Medicine, 2012, Vol 9, Issue 4, p1
- ISSN
1549-1277
- Publication type
Article
- DOI
10.1371/journal.pmed.1001201